



## DAFTAR PUSTAKA

- A. Khalil, I. (2021) 'Introductory Chapter: Pharmacogenetics, in *Pharmacogenetics*. IntechOpen. Available at: <https://doi.org/10.5772/intechopen.100403>.
- Aklillu, E. *et al.* (2011) 'Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method', *European Journal of Clinical Pharmacology*, 67(11), pp. 1139–1145. Available at: <https://doi.org/10.1007/s00228-011-1065-9>.
- Aklillu, E. *et al.* (2016) 'SLCO1B1 Gene Variations among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine', *OMICS A Journal of Integrative Biology*, 20(9), pp. 538–545. Available at: <https://doi.org/10.1089/omi.2016.0119>.
- Alsayed, S.S.R. and Gunosewoyo, H. (2023) 'Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets', *International Journal of Molecular Sciences*. Multidisciplinary Digital Publishing Institute (MDPI). Available at: <https://doi.org/10.3390/ijms24065202>.
- Al-Shaer, M.H. *et al.* (2018) 'Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar', *BMC Infectious Diseases*, 18(1). Available at: <https://doi.org/10.1186/s12879-018-3309-0>.
- Amelia, R. *et al.* (2024) 'Profile of tuberculosis patients with comorbid diabetes mellitus in Medan, Indonesia: a cross-sectional study', *Pan African Medical Journal*. African Field Epidemiology Network. Available at: <https://doi.org/10.11604/pamj.2024.49.54.36492>.
- Ang Sunarto *et al.* (2018) 'The SLCO1B1\*15 haplotype associated with lower clinical outcome in Indonesian tuberculosis patients', *Journal of the Medical Sciences (Berkala Ilmu Kedokteran)*, 50(01), pp. 50–59. Available at: <https://doi.org/10.19106/jmedsci005001201806>.
- Asemahagn, M.A. (2021) 'Sputum smear conversion and associated factors among smear-positive pulmonary tuberculosis patients in East Gojjam Zone, Northwest Ethiopia: a longitudinal study', *BMC Pulmonary Medicine*, 21(1). Available at: <https://doi.org/10.1186/s12890-021-01483-w>.
- Bailo, R. *et al.* (2022) 'The mycobacterial desaturase DesA2 is associated with mycolic acid biosynthesis', *Scientific Reports*, 12(1). Available at: <https://doi.org/10.1038/s41598-022-10589-y>.
- Butranova, O.I. *et al.* (2023) 'Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants', *Biomedicines*. MDPI. Available at: <https://doi.org/10.3390/biomedicines11030940>.
- Centers for Disease Control and Prevention (2019) *Self-Study Modules On Tuberculosis Transmission and Pathogenesis of Tuberculosis*.
- Chattopadhyay, N. *et al.* (2018) 'CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans', *British Journal of Clinical*



- Pharmacology*, 84(12), pp. 2857–2866. Available at: <https://doi.org/10.1111/bcp.13750>.
- Chen, R. *et al.* (2015) ‘Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort’, *Tuberculosis*, 95(1), pp. 68–74. Available at: <https://doi.org/10.1016/j.tube.2014.11.004>.
- Chigutsa, E. *et al.* (2011) ‘The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications’, *Antimicrobial Agents and Chemotherapy*, 55(9), pp. 4122–4127. Available at: <https://doi.org/10.1128/AAC.01833-10>.
- Dasan, B. *et al.* (2025) ‘Immunological mechanisms of tuberculosis susceptibility in TB-infected individuals with type 2 diabetes mellitus: insights from mycobacterial growth inhibition assay and cytokine analysis’, *Microbiology Spectrum*. Edited by M.R. Gitman, 13(1). Available at: <https://doi.org/10.1128/spectrum.01445-24>.
- Diacon, A.H. *et al.* (2007) ‘Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears’, *Antimicrobial Agents and Chemotherapy*, 51(8), pp. 2994–2996. Available at: <https://doi.org/10.1128/AAC.01474-06>.
- Dirjen P2P Kemenkes (2022) ‘TB control in Indonesia 2022’, *Tuberculosis Control in Indonesia 2022* [Preprint].
- Ehnert, S. *et al.* (2019) ‘One-step arms-pcr for the detection of snps—using the example of the padi4 gene’, *Methods and Protocols*, 2(3), pp. 1–14. Available at: <https://doi.org/10.3390/mps2030063>.
- Gengiah, T.N. *et al.* (2014) ‘Low rifampicin concentrations in tuberculosis patients with HIV infection’, *Journal of Infection in Developing Countries*, 8(8), pp. 987–993. Available at: <https://doi.org/10.3855/jidc.4696>.
- Guo, J. *et al.* (2025) ‘Risk factors for rifampicin-susceptible and isoniazid-resistant tuberculosis in adult patients with type 2 diabetes mellitus in Nanjing’, *BMC Infectious Diseases*, 25(1). Available at: <https://doi.org/10.1186/s12879-025-10709-9>.
- Hartkoorn, R.C. *et al.* (2010) ‘HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms’, *Pharmacogenetics and Genomics*, 20(2), pp. 112–120. Available at: <https://doi.org/10.1097/FPC.0b013e328335b02d>.
- Hermanus Suhartono S (2011) Polimorfisme Pentanukleotida (tttta)n Gen CYP11a dan Polimorfisme Gen CYP19 pada Penderita Sindroma Ovarium Polikistik (SOPK) Etnis Melanesia dan Melayu.
- Hoa, P.Q. *et al.* (2023) ‘Population Pharmacokinetic Model of Rifampicin for Personalized Tuberculosis Pharmacotherapy: Effects of SLCO1B1 Polymorphisms on Drug Exposure’, *International Journal of Antimicrobial Agents*, p. 107034. Available at: <https://doi.org/10.1016/j.ijantimicag.2023.107034>.



- Hoa, P.Q. *et al.* (2024) 'Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposure', *International Journal of Antimicrobial Agents*, 63(2). Available at: <https://doi.org/10.1016/j.ijantimicag.2023.107034>.
- Hoste, E. *et al.* (2024) 'Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy', *Clinical Biochemistry*. Elsevier Inc. Available at: <https://doi.org/10.1016/j.clinbiochem.2024.110707>.
- Huerta-García, A.P. *et al.* (2019) 'Anthropometric and Genetic Factors Associated with the Exposure of Rifampicin and Isoniazid in Mexican Patients with Tuberculosis', *Therapeutic Drug Monitoring*, 41(5), pp. 648–656. Available at: <https://doi.org/10.1097/FTD.0000000000000631>.
- Jaramillo-Valverde, L. *et al.* (2024) 'Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations', *Pharmacology Research and Perspectives*, 12(3). Available at: <https://doi.org/10.1002/prp2.1179>.
- Kementerian Kesehatan RI (2020) *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis*.
- Khan, A. *et al.* (2022) 'Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy', *Global Medical Genetics*, 09(02), pp. 090–096. Available at: <https://doi.org/10.1055/s-0042-1743567>.
- Kim, E.S. *et al.* (2021) 'Relationship among genetic polymorphism of SLCO1B1, rifampicin exposure and clinical outcomes in patients with active pulmonary tuberculosis', *British Journal of Clinical Pharmacology*, 87(9), pp. 3492–3500. Available at: <https://doi.org/10.1111/bcp.14758>.
- Kitaw, T.A. *et al.* (2025) 'Trends, prevalence, and determinants of unfavorable tuberculosis treatment outcomes among adult patients in Northeast Ethiopia: The race to achieve a 90 % treatment success rate by 2025', *Global Epidemiology*, 9. Available at: <https://doi.org/10.1016/j.gloepi.2025.100189>.
- Kivrane, A. *et al.* (2024) 'Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective', *Pharmaceutics*, 16(3). Available at: <https://doi.org/10.3390/pharmaceutics16030388>.
- Kumar, N.P. *et al.* (2019) 'Plasma proinflammatory cytokines are markers of disease severity and bacterial burden in pulmonary tuberculosis', *Open Forum Infectious Diseases*, 6(7). Available at: <https://doi.org/10.1093/ofid/ofz257>.
- Lestari, T. *et al.* (2022) 'Impacts of tuberculosis services strengthening and the COVID-19 pandemic on case detection and treatment outcomes in Mimika District, Papua, Indonesia: 2014–2021', *PLOS Global Public Health*, 2(10 October). Available at: <https://doi.org/10.1371/journal.pgph.0001114>.
- Li, W. *et al.* (2023) 'SLCO1B1 Polymorphisms are Associated with the



- Susceptibility to Pulmonary Tuberculosis in Chinese Females’, *Biochemical Genetics* [Preprint]. Available at: <https://doi.org/10.1007/s10528-023-10392-y>.
- Lima, G.C. *et al.* (2017) ‘Efficacy and safety of a four-drug fixed-dose combination regimen versus separate drugs for treatment of pulmonary tuberculosis: a systematic review and meta-analysis’, *Brazilian Journal of Microbiology*. Elsevier Editora Ltda, pp. 198–207. Available at: <https://doi.org/10.1016/j.bjm.2016.12.003>.
- Linh, N.N. *et al.* (2021) ‘World Health Organization treatment outcome definitions for tuberculosis: 2021 update’, *European Respiratory Journal*, 58(2). Available at: <https://doi.org/10.1183/13993003.00804-2021>.
- Loddenkemper, R., Lipman, M. and Zumla, A. (2016) ‘Clinical aspects of adult tuberculosis’, *Cold Spring Harbor Perspectives in Medicine*, 6(1). Available at: <https://doi.org/10.1101/cshperspect.a017848>.
- Lolong, D.B. *et al.* (2023) ‘Nonadherence to anti-tuberculosis treatment, reasons and associated factors among pulmonary tuberculosis patients in the communities in Indonesia’, *PLoS ONE*, 18(8 August). Available at: <https://doi.org/10.1371/journal.pone.0287628>.
- Luies, L. and Preez, I. du (2020) ‘The echo of pulmonary tuberculosis: Mechanisms of clinical symptoms and other disease-induced systemic complications’, *Clinical Microbiology Reviews*. American Society for Microbiology, pp. 1–19. Available at: <https://doi.org/10.1128/CMR.00036-20>.
- Mandieka, E. *et al.* (2020) ‘Latent tuberculosis infection and elevated incidence of hypertension’, *Journal of the American Heart Association*. American Heart Association Inc. Available at: <https://doi.org/10.1161/JAHA.120.019144>.
- Masago, K. *et al.* (2021) ‘Comparison between Fluorimetry (Qubit) and Spectrophotometry (NanoDrop) in the Quantification of DNA and RNA Extracted from Frozen and FFPE Tissues from Lung Cancer Patients: A Real-World Use of Genomic Tests’, *Medicina (Lithuania)*, 57(12). Available at: <https://doi.org/10.3390/medicina57121375>.
- Micaglio, E. *et al.* (2021) ‘Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine’, *Frontiers in Pharmacology*. Frontiers Media S.A. Available at: <https://doi.org/10.3389/fphar.2021.651720>.
- Mukonzo, J.K. *et al.* (2020) Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients’, *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 114(2), pp. 107–114. Available at: <https://doi.org/10.1093/trstmh/trz108>.
- Nahid, P. *et al.* (2016) ‘Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis’, *Clinical Infectious Diseases*. Oxford University Press, pp. e147–e195. Available at: <https://doi.org/10.1093/cid/ciw376>.



- Naidoo, A. *et al.* (2019) 'Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis', *Pharmacogenomics*, 20(4), pp. 224–240. Available at: <https://doi.org/10.2217/pgs-2018-0166>.
- Niward, K. *et al.* (2018) 'Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: A prospective cohort study in a low endemic setting', *Journal of Antimicrobial Chemotherapy*, 73(10), pp. 2838–2845. Available at: <https://doi.org/10.1093/jac/dky268>.
- Oshiro, C. *et al.* (2010) 'PharmGKB very important pharmacogene: SLCO1B1', *Pharmacogenetics and Genomics*, pp. 211–216. Available at: <https://doi.org/10.1097/FPC.0b013e328333b99c>.
- Pasanen, M.K. *et al.* (2006) 'Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population', *European Journal of Clinical Pharmacology*, 62(6), pp. 409–415. Available at: <https://doi.org/10.1007/s00228-006-0123-1>.
- Pedro, N. *et al.* (2020) 'Papuan mitochondrial genomes and the settlement of Sahul', *Journal of Human Genetics*, 65(10), pp. 875–887. Available at: <https://doi.org/10.1038/s10038-020-0781-3>.
- Perea-Jacobo, R. *et al.* (2022) 'SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico', *Tuberculosis*, 136. Available at: <https://doi.org/10.1016/j.tube.2022.102248>.
- Purnomo, G.A. *et al.* (2021) 'Mitogenomes reveal two major influxes of papuan ancestry across wallacea following the last glacial maximum and austronesian contact', *Genes*, 12(7). Available at: <https://doi.org/10.3390/genes12070965>.
- Purnomo, G.A. *et al.* (2024) 'The genetic origins and impacts of historical Papuan migrations into Wallacea', *Proceedings of the National Academy of Sciences of the United States of America*, 121(52). Available at: <https://doi.org/10.1073/pnas.2412355121>.
- Rahma, A.T. *et al.* (2021) 'Development of the pharmacogenomics and genomics literacy framework for pharmacists', *Human Genomics*, 15(1). Available at: <https://doi.org/10.1186/s40246-021-00361-0>.
- Rajman, I., Knapp, L. and Hanna, I. (2020) 'Genetic Diversity in Drug Transporters: Impact in African Populations', *Clinical and Translational Science*. John Wiley and Sons Inc, pp. 848–860. Available at: <https://doi.org/10.1111/cts.12769>.
- Ramachandran, G. *et al.* (2020) 'Subtherapeutic rifampicin concentration is associated with unfavorable tuberculosis treatment outcomes', *Clinical Infectious Diseases*, 70(7), pp. 1463–1470. Available at: <https://doi.org/10.1093/cid/ciz380>.
- Rambaran, S. *et al.* (2021) 'Effect of Inflammatory Cytokines/Chemokines on



- Pulmonary Tuberculosis Culture Conversion and Disease Severity in HIV-Infected and -Uninfected Individuals From South Africa', *Frontiers in Immunology*, 12. Available at: <https://doi.org/10.3389/fimmu.2021.641065>.
- Ramsey, L.B. *et al.* (2014) 'The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update', *Clinical Pharmacology and Therapeutics*. Nature Publishing Group, pp. 423–428. Available at: <https://doi.org/10.1038/clpt.2014.125>.
- Rebecca Yowaraj, M. *et al.* (2024) 'Pharmacokinetic drug-drug interaction between first-line anti-TB and anti-diabetic drugs in patients with tuberculosis and diabetes mellitus', *Indian Journal of Tuberculosis* [Preprint]. Available at: <https://doi.org/10.1016/j.ijtb.2024.10.009>.
- Roden, D.M. *et al.* (2019) 'Pharmacogenomics', *The Lancet*. Lancet Publishing Group, pp. 521–532. Available at: [https://doi.org/10.1016/S0140-6736\(19\)31276-0](https://doi.org/10.1016/S0140-6736(19)31276-0).
- Rosalinda, E. *et al.* (2024) 'Single Nucleotide Polymorphism and Restriction Enzyme Analysis of Chicken's Prolactin Gene based on Genbank Sequences', in *IOP Conference Series: Earth and Environmental Science*. Institute of Physics. Available at: <https://doi.org/10.1088/1755-1315/1360/1/012024>.
- Ruru, Y. *et al.* (2018) 'Factors associated with non-adherence during tuberculosis treatment among patients treated with DOTS strategy in Jayapura, Papua Province, Indonesia', *Global Health Action*, 11(1). Available at: <https://doi.org/10.1080/16549716.2018.1510592>.
- Salindri, A.D. *et al.* (2024) 'Tuberculosis infection and hypertension: prevalence estimates from the US National Health and Nutrition Examination Survey', *BMJ Open*, 14(3). Available at: <https://doi.org/10.1136/bmjopen-2023-075176>.
- Seijger, C. *et al.* (2019) 'High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre', *PLoS ONE*, 14(3). Available at: <https://doi.org/10.1371/journal.pone.0213718>.
- Sekaggya-Wiltshire, C. *et al.* (2018) 'Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients with Low Isoniazid and Rifampicin Concentrations', *Clinical Infectious Diseases*, 67(5), pp. 708–716. Available at: <https://doi.org/10.1093/cid/ciy179>.
- Shabani, S. *et al.* (2024) 'Pharmacogenetic Study of Drugs Affecting Mycobacterium tuberculosis', *International Journal of Mycobacteriology*, 13(2), pp. 206–212. Available at: [https://doi.org/10.4103/ijmy.ijmy\\_106\\_24](https://doi.org/10.4103/ijmy.ijmy_106_24).
- Sileshi, T. *et al.* (2022) 'Effect of Genetic Variations in Drug - Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review', *Pharmacogenomics and Personalized Medicine*. Dove Medical Press Ltd, pp. 561–571. Available at: <https://doi.org/10.2147/PGPM.S363058>.
- Sileshi, T. *et al.* (2024) 'Variability in plasma rifampicin concentrations and role



- of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis', *Infectious Diseases*, 56(4), pp. 308–319. Available at: <https://doi.org/10.1080/23744235.2024.2309348>.
- Smith, P.B. *et al.* (2019) *Rifampin Pharmacokinetics and Safety in Preterm and Term Infants on behalf of the Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee*. Available at: <https://doi.org/10.1007/s40266-023-01019-3>.
- Soraci, L. *et al.* (2023) 'Safety and Tolerability of Antimicrobial Agents in the Older Patient', *Drugs and Aging*. Adis, pp. 499–526. Available at: <https://doi.org/10.1111/j.1742-7843.2011.00838.x>.
- Sortica, V. de A. *et al.* (2012) 'Influence of Genomic Ancestry on the Distribution of SLCO1B1, SLCO1B3 and ABCB1 Gene Polymorphisms among Brazilians', *Basic and Clinical Pharmacology and Toxicology*, 110(5), pp. 460–468. Available at: <https://doi.org/10.1093/cid/ciy026>.
- Svensson, E.M. *et al.* (2018) 'The potential for treatment shortening with higher rifampicin doses: Relating drug exposure to treatment response in patients with pulmonary tuberculosis', *Clinical Infectious Diseases*, 67(1), pp. 34–41. Available at: <https://doi.org/10.3390/antibiotics9060307>.
- Thomas, L. *et al.* (2020) 'Influence of single nucleotide polymorphisms on rifampin pharmacokinetics in tuberculosis patients', *Antibiotics*. MDPI AG, pp. 1–15. Available at: <https://doi.org/10.1371/journal.pone.0226507>.
- Torres, N.M.C. *et al.* (2019) 'Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis', *PLoS ONE*, 14(12). Available at: <https://doi.org/10.1128/AAC.00353-10>.
- Weiner, M. *et al.* (2010) 'Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations', *Antimicrobial Agents and Chemotherapy*, 54(10), pp. 4192–4200. Available at: <https://doi.org/10.1016/j.anthro.2023.103157>.
- Widianto, H. and Noerwidi, S. (2023) 'Australo-melanesian: Human population in Indonesian Archipelago during the Pleisto-Holocene transition', *Anthropologie (France)*, 127(3). Available at: <https://doi.org/10.1128/AAC.00353-10>.
- World Health Organization (2022) *WHO operational handbook on tuberculosis Module 4: Treatment Drug-susceptible tuberculosis treatment*.
- World Health Organization (2023a) *Global tuberculosis report 2023*. Available at: <https://iris.who.int/>.
- World Health Organization (2023b) *Global Tuberculosis Report 2023*. Available at: <https://iris.who.int/>.
- Xu, L.Y. *et al.* (2007) 'Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients', *Acta Pharmacologica Sinica*, 28(10), pp. 1693–1697. Available at: <https://doi.org/10.2147/TACG.S144383>.
- Yang, L. *et al.* (2018) 'Evaluation of amplification refractory mutation system (ARMS) technique for quick and accurate prenatal gene diagnosis of CHM variant in choroideremia', *Application of Clinical Genetics*, 11, pp. 1–8. Available at: <https://doi.org/10.2147/TACG.S144383>.